Background Olaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice-daily dose; a tablet formulation was developed to reduce pill burden. This clinical trial evaluated the optimal dose and administration schedule of the tablet formulation. Patients and Methods Two stages of sequentially enrolled cohorts: stage 1, pharmacokinetic properties of tablet and capsule formulations were compared in patients with advanced solid tumours; stage 2, tablet dose escalation with expansion cohorts at doses/schedules of interest in patients with solid tumours and BRCAm breast/ovarian cancers. Results Olaparib 200 mg tablets displayed similar C max,ss , but lower AUC ss and C min,ss than 400 mg capsules.
Following multiple dosing, steady-state exposure with tablets ≥300 mg matched or exceeded that of 400 mg capsules. After dose escalation, while 400 mg twice daily was the tablet maximum tolerated dose based on haematological toxicity, 65 % of patients in the randomized expansion phase eventually required dose reduction to 300 mg. Intermittent tablet administration did not significantly improve tolerability. Tumour shrinkage was similar for 300 and 400 mg tablet and 400 mg capsule cohorts. Conclusions The recommended monotherapy dose of olaparib tablet for Phase III trials was 300 mg twice daily, simplifying drug administration from 16 capsules to four tablets per day. Clinical Trial Number NCT00777582 (ClinicalTrials.gov)
Electronic supplementary material The online version of this article (doi:10.1007/s11523-016-0435-8) contains supplementary material, which is available to authorized users.
Introduction
Poly(ADP-ribose) polymerases (PARPs) play a key role in detecting DNA damage and triggering activation of DNA repair pathways. Two seminal publications laid the foundation for clinical development of PARP inhibitors in the treatment of cancers harbouring a BRCA1/2 mutation [1, 2] . Individuals carrying BRCA mutations (BRCAm) account for 15 % of cases of high-grade serous ovarian carcinoma [3, 4] and 10-20 % of cases of triple-negative breast cancer (oestrogen receptor, progesterone receptor, and HER2-negative tumours) [5, 6] .
A proof-of-concept clinical trial of olaparib (Lynparza™), a potent oral inhibitor of PARP1 and PARP2, established 400 mg capsule (CAP) formulation twice daily (BD) as the maximum tolerated dose (MTD) [7] . Drug exposure increased proportionally with doses up to 100 mg BD, with less-marked increases above this threshold, and pharmacodynamic (PD) effects plateaued at doses >60 mg BD. However, further clinical trials in breast and ovarian BRCAm cancer suggested a dose-response relationship, supporting use of the MTD of olaparib over a minimal biologically effective dose [8] [9] [10] .
Subsequent Phase II studies of olaparib confirmed the sustained antitumour activity in patients with germline BRCAm (gBRCAm) high-grade serous epithelial ovarian [8, 10] , breast and other tumour types [9, 11] ; olaparib antitumour activity was also observed in sporadic cancers [12] . BBRCAness^is used to refer to tumours with BRCA-like genomic or post-transcriptional aberrations, suggesting a wider application of PARP inhibitors [13] [14] [15] beyond tumours associated with BRCAm. In a randomized Phase II study in patients with platinum-sensitive recurrent ovarian cancer, olaparib maintenance therapy improved progression-free survival (PFS) and patients with BRCAm were most likely to benefit from treatment [16, 17] . In December 2014, the CAP formulation of olaparib received EU [18] and US [19] approval. To receive the approved 400 mg BD CAP dose, patients need to take 8x50 mg large size 0 capsules twice daily. To improve dosing constraints of the CAP formulation, a meltextrusion tablet (TAB) formulation with improved bioavailability was developed.
We report results of an open-label, multicentre, multistage, Phase I trial comparing the pharmacokinetics (PK), efficacy and tolerability of different doses and scheduling of the olaparib CAP and TAB formulations to determine an optimal TAB dosing strategy for Phase III studies of olaparib.
Patients and Methods

Study Design
The Phase I study was conducted in two sequential stages ( O n l i n e R e s o u r c e 1 , S u p p l e m e n t a r y F i g u r e 1 ; ClinicalTrials.gov NCT00777582): stage 1 was a randomized, two-period, crossover design to determine the comparative bioavailability of the two formulations (bioavailability assessment; patients could then enter a continued-supply phase [CSP; cohorts 1-3]) followed by a dose-expansion phase (groups 1-2) to validate PK modelling and determine steady-state PK; stage 2 determined the MTD and optimum schedule of the TAB formulation (using dose-escalation [groups 3-5.2] and dose-expansion, randomized TAB/CAP comparison [group 6]; dose-expansion, randomized TAB alternative dosing schedules, group 8).
Institutional review boards/independent ethics committees of the 10 investigational sites approved the protocol. All patients provided written informed consent. The study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice, and the AstraZeneca policy on bioethics [20] .
Stage 1: Bioavailability Assessment
Patients were randomized to two treatment periods of olaparib CAP and TAB, separated by a 6-to 14-day washout, to study the PK profile at different dose levels (Online Resource 1, Supplementary Figure 1) . On completion, patients could enter a CSP, where they received olaparib 400 mg BD CAP until disease progression, unacceptable toxicity or withdrawal of consent. Based on an estimate of intra-subject variability following CAP dosing, a sample size of six patients for each dose level was expected to produce a 90 % confidence interval (CI) of 1.61-2.49 for the comparative bioavailability assessment. PK modelling and simulation was performed to select a TAB dose expected to have comparable steady-state maximum plasma concentration (C max ) and area under the plasma concentration-time curve (AUC) to the 400 mg BD CAP dose.
Once the TAB dose was determined, a dose-expansion phase was initiated to validate PK modelling for the selected TAB and 400 mg BD CAP (group 1). A second group of six patients (group 2) was randomly assigned to one of two treatment sequences: selected TAB dose BD days 1-8 followed by 400 mg BD CAP days 9-15 or vice versa. After day 15, all p a ti e n t s r e c e i v e d s e l e c t e d TAB un ti l t r e a t m e n t discontinuation.
Primary objectives of stage 1 were to determine comparative bioavailability of the TAB and CAP formulations and to assess safety and tolerability (group 1). Secondary objectives were to: generate single-dose PK data and information on dose linearity of the TAB formulation; assess preliminary efficacy of the TAB and CAP formulations (group 1); compare steadystate exposure achieved with selected TAB and 400 mg BD CAP (group 2).
Stage 2: Dose-Schedule Optimization
Stage 1 data indicated that higher TAB doses should be explored. The protocol was amended to include a second stage with a rolling dose-escalation design (groups 3-5.2). The MTD was defined as the maximum dose at which ≥33 % of patients experienced dose-limiting toxicities (DLTs).
Following completion of dose escalation, a randomized safety and efficacy comparison between the selected TAB dose levels and the original CAP regimen was conducted in patients with gBRCAm breast or ovarian cancer (group 6).
To assess tolerability and scheduling of the higher daily doses, the protocol was amended to recruit patients with gBRCAm ovarian cancer in a further randomized group using alternative TAB schedules (group 8). Patients were randomized 1:1:1:1 to: schedule A, 200 mg three times daily (TID); schedule B, 250 mg TID 2 weeks on, 1 week off; schedule C, 400 mg BD 1 week on, 1 week off; or schedule D, 400 mg once daily (QD).
Primary objectives of stage 2 were to: determine safety and tolerability profile of doses higher than 200 mg BD TAB (groups 3-5.2); compare safety of higher TAB doses with 400 mg CAP dose in gBRCAm breast or ovarian cancer patients (group 6); and determine safety and tolerability of alternative TAB schedules in gBRCAm breast or ovarian cancer patients (group 8). Secondary objectives were to: determine single-dose and steady-state exposures with higher doses and selected schedules of TAB (groups [3] [4] [5] 8) ; compare singledose and steady-state exposures of TAB with 400 mg CAP; and assess efficacy in patients treated with TAB or CAP (groups 6, 8). Only patients with gBRCAm breast or ovarian cancer were recruited into groups 1 and 6. Group 8 was limited to gBRCAm patients with ovarian, primary peritoneal or fallopian tube cancer. These groups were required to have at least one measurable lesion.
Patients
Study Endpoints and Assessments
Assessments included medical review, physical examination, vital signs, and clinical laboratory tests and were performed weekly during the first 4 weeks and 4-weekly thereafter. Adverse events (AEs) were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v3.0. DLT was defined as any of the following AEs occurring in the first 28 days of treatment and judged by the investigators to be related to olaparib: grade (G) 4 neutropenia lasting >5 days or associated with fever; G4 thrombocytopenia; G ≥ 2 cardiac or neurological toxicity; any AE that delayed the start of course 2 for >14 days from the planned date; or other G3-4 events, except fatigue, nausea and vomiting, diarrhoea, myalgia, or arthralgia, unless appropriate prophylactic/ therapeutic measures have been administered. Guidelines for management of common toxicities were implemented at investigational sites, including uniform rules for dose modifications. Radiological assessments were performed every 8 weeks according to Response Criteria in Solid Tumors (RECIST) v1.0. Tumour shrinkage, objective response rate (ORR), and response rate in ovarian cancer were based on CA-125 (GCIG) and RECIST [21, 22] .
Pharmacokinetics and Modelling Analysis
Blood samples were collected at pre-specified times during stages 1 and 2 of the study. Primary outcome variables to determine the comparative bioavailability of the TAB and CAP formulations were single-dose C max , AUC and AUC to time t (AUC 0-t ). Single-dose PK parameters of time to maximum plasma concentration (t max ), oral clearance (CL/F), terminal half-life (t ½ ) and volume of distribution (V area /F) were also determined. Multiple-dose PK parameters for groups 1, 2, and 3-8 of the dose-escalation phase and the randomized TAB formulations included assessment of AUC ss , C max,ss , and C min,ss .
PK parameters for the comparative bioavailability phase and group 2 CAP/TAB crossover phase were generated using standard non-compartmental analysis. PK data from the bioavailability assessment cohorts were used to build a population PK model for olaparib by fitting a two-compartment model with first-order absorption, first-order elimination and a lag time to the data. The population parameter and interindividual variability estimates obtained from this model were used to predict the TAB dose, with expected steady-state plasma exposures within the range of those observed following dosing of the 400 mg BD CAP dose by simulating multipledose PK parameters (C max,ss , AUC ss ) following administration of the TAB formulation at 1-250 mg BD doses for a patient population of 10,000. The C max,ss and AUC 0-12,ss values obtained were compared with previously determined ranges following 400 mg BD CAP dosing, and the percentage of patients with values within these ranges was determined for each TAB dose. The chosen TAB dose for groups 1 and 2 was predicted to provide a C max,ss and AUC ss within the 400 mg CAP range for these parameters in 95 % of patients. In group 1 and in stage 2 (groups 3-8), C max,ss , C min,ss , and AUC ss at different doses and schedules of TAB were determined following sparse PK sampling and analysed using the same population PK model.
Pharmacodynamics
Methodology and results of the PD analysis are provided in Online Resource 1, Supplementary Table 2.
Statistical Analysis
The extent of exposure, AEs, DLTs, and percentage inhibition of PARP in peripheral blood mononuclear cells were summarized with descriptive statistics. Single-dose PK, linearity, and comparative bioavailability were assessed in stage 1.
In stage 1, plasma concentration data, PK and PD parameters were summarized descriptively by dose level and formulation administered. Within each cohort, comparative bioavailability and 90 % CIs were estimated using analysis of variance with factors for patient, formulation and period.
A planned comparison of the preliminary data on antitumour activity in patients with ovarian cancer in groups 1, 6, and 8 was conducted, based on analysis of covariance (ANCOVA) of the percentage change in tumour size after 8 and 16 weeks of treatment, using comparator data from all ovarian cancer patients receiving the CAP formulation. The ANCOVA models were adjusted for baseline tumour size and, additionally for group 8, prior platinum chemotherapy status (with categories for resistant, sensitive and no prior platinum use/unknown) [23] , number of prior chemotherapy regimens (discrete variable) and peritoneal involvement at baseline (as a dichotomous variable); the latter two variables were identified as possible prognostic factors based on exploratory analysis of data from the olaparib clinical programme.
Ruling out a 20 % difference (based on <20 % one-sided 80 % upper confidence limit [UCL]) was used as a definition of non-inferiority for a given TAB dose compared with the 400 mg BD CAP formulation. This difference was based on Phase II studies comparing 100 and 400 mg CAP-based doses [8, 9] . Table 1 ; all patients had metastatic or locally advanced non-resectable disease at enrolment.
Stage 1
Ovarian, breast, and colorectal cancers were the most common tumour types (Table 1) . Median time on treatment was 87 days for patients in the PK phase (PKP)/CSP (cohorts 1-3).
Stage 2
Patients in the dose-escalation (groups 3-5.2; n = 31) and dose-expansion phase of stage 2 (groups 6 and 8; n = 115) had ovarian (n = 114) or breast (n = 27) cancer, with the exception of five patients (n = 1 each; metastatic castration-resistant prostate cancer, gastric cancer, uterine leiomyosarcoma, renal cell carcinoma, oesophageal-gastric junction carcinoma). Sixty-two gBRCAm patients with ovarian, primary peritoneal, or fallopian tube cancer were randomized to receive the four alternative TAB schedules (group 8). Patients in groups 6 and 8 had confirmed gBRCAm; gBRCAm status for groups 1, 6, and 8 are reported in Online Resource 1, Supplementary Table 3 .
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Bioavailability Assessment
Following PK analysis for single doses of 25 and 50 mg TAB in cohorts 1 and 2, a 250 mg dose was selected for cohort 3, assuming dose proportionality would occur at TAB doses >50 mg and exposures would not exceed those previously achieved following ≤600 mg CAP [7] . In all three cohorts (1-3; Fig. 1 and Online Resource 1, Supplementary Table 4) , absorption was rapid, with maximum concentrations observed 0.5-2 h after TAB dosing (compared with 1-3 h for CAP [50, 100, and 400 mg doses]). Following this peak, plasma concentration-time profiles declined biphasically, with a t ½ of 5-9 h and no change in t ½ with increasing dose. The overall mean t ½ for TAB was 6.97 h (standard deviation [SD] 1.06 h). The mean (SD) CL/F and V area /F was 5.42 (2.60) L/h and 54.9 (30.1) L, respectively. Exposure increased approximately dose proportionally, with geometric mean (gmean) C max increasing 1.9-and 7.5-fold, and gmean AUC increasing 1.6-and 12.2-fold, respectively, for a two-and 10-fold dose increase.
The relative bioavailability of TAB doses compared with CAP was higher based on C max ratios; however, AUC ratios were similar at the two lower TAB doses (Online Resource 1, Supplementary Table 4) . Exposure following CAP dosing increased less than proportionally at doses >100 mg, and both C max and AUC values were higher with 250 mg TAB than with the comparative CAP dose (400 mg). Based on geometric least squares mean (gLSmean) C max and AUC ratios and 90 % CIs from the 18 patients in these three cohorts, the TAB and CAP formulations cannot be considered bioequivalent. Further PK modelling and simulation of data predicted that a 200 mg BD TAB dose would deliver steady-state C max and AUC 0-12 values within the range observed for patients receiving 400 mg BD CAP. To validate these modelling results, six additional patients received 200 mg TAB and 400 mg CAP in a crossover design (group 2). Although gmean C max,ss was similar, gmean AUC ss was~20 % lower and gmean C min,ss 50 % lower following 200 mg TAB versus 400 mg CAP (Online Resource 1, Supplementary Table 4) . Further assessment of steady-state PK was conducted during stage 2; gmean C max,ss , C min,ss , and AUC 0-12,ss with 300 and 400 mg TAB BD in the expansion cohorts exceeded those achieved with the 400 mg BD CAP dose (Table 2 ).
Safety and Tolerability
Tables 3 (dose-expansion and dose-escalation cohorts) and 4 (expansion phase, alternative dosing schedule cohorts) list the median exposure to olaparib, the most commonly reported AEs (Table 4 Table 6 summarizes haemoglobin toxicity for groups 6 and 8.
During TAB dose escalation, the 450 mg BD dose level was deemed non-tolerable; G3 anaemia, thrombocytopenia and neutropenia occurred in 3/6 (50 %), 1/6 (17 %), and 1/6 patients (17 %), respectively; overall, 5/6 patients (83 %) required a dose reduction because of drug-related AEs. The Eight patients in the dose-expansion phase required permanent discontinuation of olaparib because of an AE across dose levels (n = 1 patient each: nausea; vomiting; rash; increased AST; increased ALT; small intestinal obstruction; myalgia and rash [both AEs in one patient]; large intestinal obstruction a Only subjects remaining on the starting dose at day 29 were included in the summary statistics. All data expressed as gmean (range) (n = 11) (n = 6) (n = 6) (n = 6) (n = 6) (n = 6) (n = 18) (n = 17) (n = 18) and vomiting [both AEs in one patient]). There were seven deaths altogether; all were related to the disease under investigation. Three of these deaths had an intercurrent serious AE (n = 1 patient each: pneumocystis carinii pneumonia; intraabdominal haemorrhage; small intestinal obstruction). The AE of pneumocystis carinii pneumonia was thought to be secondary to bone pancytopenia and was considered by the investigator as related to olaparib. When considering all patients who received 300 or 400 mg BD TAB (during dose-escalation and randomized expansion phases), 7/24 (29 % [22 % in randomized expansion phase]) and 14/23 (61 % [65 % in randomized expansion phase]) patients required ≥1 dose reduction because of AEs (mainly due to gastrointestinal toxicities, fatigue, anaemia), respectively. Six patients who started at 400 mg TAB BD required ≥2 dose de-escalations; dose reductions were more common during the first two cycles of therapy compared with other doses and CAP. Online Resource 1, Supplementary Table 7 summarizes drug interruptions and dose reductions for groups 6 and 8. Median time on treatment for ovarian cancer patients receiving 400 mg TAB BD was 212 days, although the median duration for patients receiving the cohort starting dose of 400 mg TAB BD before requiring a dose modification was only 51 days.
Intermittent dosing (group 8) did not affect patient adherence to treatment; mean compliance was 94.6-97.4 % across schedules. For the alternative-scheduling cohorts (group 8), the inclusion criteria were amended to restrict enrolment for patients with higher baseline haemoglobin (Online Resource 1, Supplementary Table 1 ), resulting in a lower incidence of anaemia overall (12 cases, 19.4 %) relative to the patients in the previous expansion cohorts (groups 1 and 6; 22/64, Table 4 Summary of actual treatment exposure and number (%) of patients who had at least one AE of any grade (occurring in more than three patients in any treatment group) and AEs of grade ≥3 (occurring in more than one patient) in group 8 (expansion phase, alternative olaparib dosing schedules) (6) 10 (67) 1 (7) 12 (75) 3 (19) 6 (40) 1 (7) General disorders Fatigue 8 (50) 2 (13) 8 ( 34.4 %). Three and two cases of G3 anaemia were observed in the intermittent and continuous-dosing groups (3/31, 9.6 %; 2/31, 6.4 %; Table 4 ), respectively. The most common AEs observed in group 8 were nausea and vomiting (reported in 82 and 68 % of patients, respectively; Table 4 ). Intermittent administration of 400 mg BD led to G3 vomiting in 18.8 % of cases (3/16 patients), while only one case was reported in each of the other dose schedules (6-7 %). Moreover, the 400 mg BD intermittent dose level had the most patients requiring dose reductions (6/16, 37.5 %) because of AEs, compared with 6.7-18.8 % of patients in the other dose schedules.
Antitumour Activity in gBRCAm Carriers and Serous Ovarian Carcinoma
The radiological ORR in gBRCAm carriers with serous ovarian carcinoma from groups 1 and 6 (n = 53 total: 200 mg BD TAB, n = 8; 300 mg BD TAB, n = 13; 400 mg BD TAB, n = 12; 400 mg BD CAP, n = 20) was 30 % (16/53; 95 % CI 18.3-44.3) across cohorts, although it appeared higher for patients receiving 300 mg TAB BD (5/13, 38 %; 95 % CI 13.9-68.4) and 400 mg TAB BD (5/12, 42 %; 95 % CI 15.2-72.3). The RR based on a RECIST response and/or CA-125 was 40 % (21/53, 95 % CI 26.5-54.0).
Analysis of the percentage change in tumour size after 8 and 16 weeks of treatment showed similar efficacy for both 300 and 400 mg TAB compared with 400 mg BD CAP. The one-sided upper limit of the 80 % CI was below the pre-specified criteria of 20 % compared with the original formulation (400 mg BD CAP) for both groups at 300 mg BD TAB (LSmean change in tumour size at week 8: 1.8 %, one-sided 80 % UCL 12.1) and 400 mg BD TAB (LSmean change in tumour size at week 8: −10.5 %, one-sided 80 % UCL 0), indicating similar efficacy. However, the 200 mg BD CAP dose failed to meet the criteria to be considered similar to 400 mg BD CAP (difference in LSmeans at week 8: 8.6 %, one-sided 80 % UCL 21.1). Consistent results were obtained after 16 weeks of therapy (Tables 5  and 6 , Online Resource 1, Supplementary Figure 2 ). For patients in the alternative-scheduling cohorts (group 8), only 200 mg TID continuous and 400 mg BD intermittent dose schedules were considered non-inferior to 400 mg BD CAP (Table 6 , Online Resource 1, Supplementary  Figure 2 ). 
Discussion
This adaptive trial was planned as a comparative bioavailability study to select the optimal dose of a TAB olaparib formulation so as to simplify drug administration. Prior clinical trials using the CAP olaparib formulation reported a direct association between dose and antitumour activity in gBRCAm carriers [8] [9] [10] . We conducted a comparison of olaparib TAB bioavailability, efficacy, and safety with those of 400 mg CAP BD and identified 300 mg TAB BD as the recommended TAB monotherapy dose for investigation in olaparib Phase III clinical trials. PK modelling predicted that a 200 mg BD TAB dose would deliver multiple-dose exposure within the range of exposures observed with 400 mg BD CAP [7] . However, direct intra-subject comparison of steady-state exposure for the six patients treated at 200 mg BD TAB showed that, although the gmean C max,ss achieved was similar to 400 mg BD CAP, gmean AUC ss and C min,ss were approximately 20 and 50 % lower, respectively. Consequently, stage 2 of the study was pursued to assess tolerability and antitumour activity of higher TAB doses.
The dose-escalation phase established 400 mg BD TAB as the MTD based on haematological toxicities at 450 mg BD. However, as patient numbers in this phase were small, a randomized comparison between 300 mg BD TAB (lowest dose achieving similar drug exposure to the CAP recommended dose), 400 mg BD TAB (the defined TAB MTD) and the original 400 mg CAP regimen was performed to better determine the tolerability profiles. The 250 mg BD tablet dose was not pursued during this stage of the study for several reasons, including the findings from the PK/PD modelling, the linear nature of the way the study was performed (i.e. the 200, 300, and 400 mg tablet dose expansions were not performed in parallel), and the extensive overlap in exposure between the 250 and 300 mg doses. It was, therefore, not deemed necessary to pursue both 250 and 300 mg tablet doses. For patients who were receiving 400 mg BD TAB in the randomized dose-expansion phase, the number of anaemia and gastrointestinal AEs, as well as the number of patients requiring dose reductions, confirmed that olaparib 400 mg BD TAB was not optimally tolerated in this population of heavily pre-treated breast and ovarian cancer patients. Analysis for group 8 was performed using an analysis of covariance with factors for treatment group, baseline sum of target lesions, prior platinum chemotherapy status, number of prior chemotherapy regimens and whether there was peritoneal involvement at baseline OD once daily a Data from the 400 mg BD capsule arm from ovarian cancer patients in groups 1 and 6 have been combined to use as a comparator in analyses
Although antitumour activity was not a primary objective of this study and there were limited numbers of patients in each dose subgroup, it is noteworthy that this is one of the largest series of gBRCAm carriers receiving a single-agent PARP inhibitor. The overall response rate across the different cohorts was 30 % in gBRCAm ovarian cancer patients; these data further support the confirmed anticancer activity of olaparib in patients with a gBRCAm [11, 17] . For ovarian cancer patients, the analysis of preliminary data on antitumour activity showed that 300 mg BD TAB was similar to the approved dose of 400 mg BD CAP.
We also evaluated olaparib administered in different schedules based on the hypothesis that different patterns of drug exposure may help alleviate common AEs of anaemia, nausea or vomiting. Intermittent PARP inhibition has been investigated in several combinatory trials, mainly with cytotoxic chemotherapy [24] [25] [26] , but this is, to our knowledge, the first series of patients prospectively enrolled to receive a singleagent PARP inhibitor in different intermittent schedules. In these cohorts, intermittent scheduling did not improve gastrointestinal tolerability; indeed, nausea, vomiting, or diarrhoea seemed to be better controlled by reducing the daily amount of drug administered. However, this cohort was conducted only in patients with advanced ovarian carcinoma, where serosal bowel involvement is a common cause of gastrointestinal symptoms, and may not be generalizable to other tumour types. Additionally, preclinical data have indicated that continuous inhibition of PARP is required for maximum efficacy (unpublished data), further supporting continuous rather than intermittent dosing for olaparib monotherapy. Administration of the 600 mg total daily dose as a TID schedule (200 mg TID), while showing similar efficacy, was not considered to improve tolerability over 300 mg BD, with additional patient inconvenience of TID dosing.
Conclusion
In conclusion, this multistage clinical trial showed that patients' exposure following tablet doses ≥300 mg BD matched or exceeded that of the approved 400 mg BD CAP (8 × 50 mg capsules BD). A dose of 300 mg BD TAB was better tolerated than higher doses, with similar clinical activity in terms of tumour shrinkage. None of the intermittent-dosing schedules explored improved both efficacy and tolerability relative to 300 mg BD continuous dosing. Therefore, continuous dosing of olaparib tablets 300 mg BD (2 × 150 mg tablets BD) is recommended for olaparib Phase III clinical trials, simplifying drug administration from 16 capsules to four tablets per day.
